Differential immunogenicity of vaccinia and HIV-1 components of a human recombinant vaccine in mucosal and blood compartments

被引：11
作者：
Anton, Peter A. [1 ,2 ]
Ibarrondo, F. Javier [1 ,2 ]
Boscardin, W. John [1 ,2 ,4 ]
Zhou, Ying [1 ,2 ,4 ]
Schwartz, Elissa J. [6 ,7 ]
Ng, Hwee L. [1 ,2 ,4 ]
Hausner, Mary Ann [1 ,2 ]
Shih, Roger [1 ,2 ]
Elliott, Julie [1 ,2 ]
Hultin, Patricia M. [1 ,2 ]
Hultin, Lance E. [1 ,2 ]
Price, Charles [1 ,2 ]
Fuerst, Marie [8 ]
Adler, Amy [1 ,2 ]
Wong, Johnson T. [5 ]
Yang, Otto O. [1 ,2 ,3 ]
Jamieson, Beth D. [1 ,2 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, UCLA AIDS Inst, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Ctr Prevent Res, Los Angeles, CA 90095 USA
[3] Univ Calif Los Angeles, David Geffen Sch Med, Dept Microbiol Iimmunol & Mol Genet, Los Angeles, CA 90095 USA
[4] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA
[5] Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp, Boston, MA USA
[6] Washington State Univ, Dept Math, Pullman, WA 99164 USA
[7] Washington State Univ, Sch Biol Sci, Pullman, WA 99164 USA
[8] Tower Canc Res Fdn, Beverly Hills, CA USA
来源：
VACCINE | 2008年 / 26卷 / 35期
关键词：
mucosal immunity; HIV; vaccine;
D O I：
10.1016/j.vaccine.2008.05.084
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Mucosal immune responses induced by HIV-1 vaccines are likely critical for prevention. We report a Phase 1 safety and immunogenicity trial in eight participants using the vaccinia-based TBC-3B vaccine given subcutaneously to determine the relationship between HIV-1 specific systemic and gastrointestinal mucosal responses. Across all subjects, detectable levels of blood vaccinia- and HIV-1-specific antibodies were elicited but none were seen mucosally. While the vaccinia component was immunogenic for CD8(+) T lymphocyte (CTL) responses in both blood and mucosa, it was greater in blood. The HIV-1 component of the vaccine was poorly immunogenic in both blood and mucosa. Although only eight volunteers were studied intensively, the discordance between mucosal and blood responses may highlight mechanisms contributing to recent vaccine failures. (c) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码：4617 / 4623
页数：7
相关论文
共 39 条
  • [1] Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients
    Ackers, ML
    Parekh, B
    Evans, TG
    Berman, P
    Phillips, S
    Allen, M
    McDougal, JS
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2003, 187 (06) : 879 - 886
  • [2] Enhanced levels of functional HIV-1 co-receptors on human mucosal T cells demonstrated using intestinal biopsy tissue
    Anton, PA
    Elliott, J
    Poles, MA
    McGowan, IM
    Matud, J
    Hultin, LE
    Grovit-Ferbas, K
    Mackay, CR
    Chen, ISY
    Giorgi, JV
    [J]. AIDS, 2000, 14 (12) : 1761 - 1765
  • [3] Sensitive and reproducible quantitation of mucosal HIV-1 RNA and DNA viral burden in patients with detectable and undetectable plasma viral HIV-1 RNA using endoscopic biopsies
    Anton, PA
    Poles, MA
    Elliott, J
    Mao, SH
    McGowan, I
    Lenz, HJ
    Chen, ISY
    [J]. JOURNAL OF VIROLOGICAL METHODS, 2001, 95 (1-2) : 65 - 79
  • [4] Belyakov Igor M, 2004, Expert Rev Vaccines, V3, pS65, DOI 10.1586/14760584.3.4.S65
  • [5] Impact of vaccine-induced mucosal high-avidity CD8+CTLs in delay of AIDS viral dissemination from mucosa
    Belyakov, IM
    Kuznetsov, VA
    Kelsall, B
    Klinman, D
    Moniuszko, M
    Lemon, M
    Markham, PD
    Pal, R
    Clements, JD
    Lewis, MG
    Strober, W
    Franchini, GA
    Berzofsky, JA
    [J]. BLOOD, 2006, 107 (08) : 3258 - 3264
  • [6] Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers
    Broliden, K
    Hinkula, J
    Devito, C
    Kiama, P
    Kimani, J
    Trabbatoni, D
    Bwayo, JJ
    Clerici, M
    Plummer, F
    Kaul, R
    [J]. IMMUNOLOGY LETTERS, 2001, 79 (1-2) : 29 - 36
  • [7] Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation
    Buonaguro, L
    Visciano, ML
    Tornesello, ML
    Tagliamonte, M
    Biryahwaho, B
    Buonaguro, FM
    [J]. JOURNAL OF VIROLOGY, 2005, 79 (11) : 7059 - 7067
  • [8] Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers
    Cebere, I
    Dorrell, L
    McShane, H
    Simmons, A
    McCormack, S
    Schmidt, C
    Smith, C
    Brooks, M
    Roberts, JE
    Darwin, SC
    Fast, PE
    Conlon, C
    Rowland-Jones, S
    McMichael, AJ
    Hanke, T
    [J]. VACCINE, 2006, 24 (04) : 417 - 425
  • [9] Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate
    Devito, C
    Hinkula, J
    Kaul, R
    Lopalco, L
    Bwayo, JJ
    Plummer, F
    Clerici, M
    Broliden, K
    [J]. AIDS, 2000, 14 (13) : 1917 - 1920
  • [10] Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity
    Devito, C
    Zuber, B
    Schröder, U
    Benthin, R
    Okuda, K
    Broliden, K
    Wahren, B
    Hinkula, J
    [J]. JOURNAL OF IMMUNOLOGY, 2004, 173 (11) : 7078 - 7089
1234